Almirall, S.A.
LBTSF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.34B
Close$
$18.01
17.4% upside
Current Fair Value
17.4% upsideUndervalued by 17.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.34 Billion |
|---|---|
| Enterprise Value | $3.36 Billion |
| Annual dividend | $0.22 |
| Dividend yield | 1.78% |
| Earnings per Share | $0.21 |
| Beta | 0.18 |
| Outstanding Shares | 217,742,000 |
Return
| Return on Equity | 4.69% |
|---|---|
| Return on Assets | 3.03% |
| Return on Invested Capital | 14.34% |
Valuation & Multiples
| P/E Ratio | 31.27 |
|---|---|
| PEG | 8.07 |
| Price to Sales | 2.56 |
| Price to Book Ratio | 2.19 |
| Enterprise Value to Revenue | 2.38 |
| Enterprise Value to EBIT | 11.47 |
| Enterprise Value to Net Income | 46 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 24, 2026
EPS Estimate
$0.15
Consensus analyst estimateRevenue Estimate
$357.09 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$0.15
Consensus analyst estimateRevenue Estimate
$354.30 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Almirall, S.A.
2,097 employees
CEO: Carlos Gallardo Piqué
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the Unite...